Get the Stockscreener App
3.83
3.77%
-0.15
After Hours:
3.90
0.07
+1.83%
Ventyx Biosciences Inc stock is traded at $3.83, with a volume of 1.39M.
It is down -3.77% in the last 24 hours and up +60.92% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$3.98
Open:
$4
24h Volume:
1.39M
Relative Volume:
1.40
Market Cap:
$273.11M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-1.1606
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
+6.39%
1M Performance:
+60.92%
6M Performance:
+318.76%
1Y Performance:
+86.83%
1-Day Range:
$3.69
$4.04
1-Week Range:
$3.36
$4.05
52-Week Range:
$0.783
$4.05
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
3.83 | 283.81M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Is Ventyx Biosciences Inc. stock a safe buy before earningsEarnings Miss & Verified Trade Idea Suggestions - newser.com
Is Ventyx Biosciences Inc. stock in correction or buying zoneJuly 2025 Final Week & Proven Capital Preservation Tips - newser.com
What’s the recovery path for long term holders of Ventyx Biosciences Inc.Market Growth Summary & Weekly Setup with High ROI Potential - newser.com
Signal strength of Ventyx Biosciences Inc. stock in tech scanners2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Is Ventyx Biosciences Inc. stock a top pick in earnings seasonAnalyst Upgrade & Breakout Confirmation Alerts - newser.com
Analyzing recovery setups for Ventyx Biosciences Inc. investorsJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - newser.com
Tools to assess Ventyx Biosciences Inc.’s risk profileGap Up & Risk Adjusted Swing Trade Ideas - newser.com
Sentiment analysis tools applied to Ventyx Biosciences Inc.2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
Published on: 2025-10-02 23:37:22 - earlytimes.in
What drives Ventyx Biosciences Inc stock priceDividend Stability Analysis & Free Tremendous Return On Equity - earlytimes.in
Clear Street Initiates Coverage of Ventyx Biosciences (VTYX) with Buy Recommendation - Nasdaq
Ventyx Biosciences Inc Stock Analysis and ForecastStock Buy Signals & Create Your Free Watchlist Instantly - earlytimes.in
Analyst Coverage Initiation: VTYX Receives a 'Buy' Rating | VTYX Stock News - GuruFocus
Ventyx Biosciences stock initiated with Buy rating at Clear Street By Investing.com - Investing.com Canada
Clear Street Initiates Ventyx Biosciences(VTYX.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Ventyx Biosciences stock initiated with Buy rating at Clear Street - Investing.com India
Will Ventyx's Dual NLRP3 Trials Pave The Way For CNS And Cardiometabolic Expansion? - RTTNews
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ventyx Biosciences Inc Stock (VTYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '25 |
Option Exercise |
0.00 |
11,844 |
0 |
2,303,540 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '25 |
Option Exercise |
0.00 |
4,531 |
0 |
469,113 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 27 '24 |
Sale |
2.36 |
21,119 |
49,841 |
464,582 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):